Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.65 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.65 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | CD69 | Q07108 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | AMY2A | P04746 | 2/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8723962 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL8723958 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL29425222 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL1078078 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL9398176 | 0.99 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL10524839 | 0.99 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL17050874 | 0.99 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL14268473 | 0.99 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL20555908 | 0.99 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL117333 | 0.99 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587842-A1 | BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND SUPERMILD TRAUMATIC BRAIN INJURY | Abbott Laboratories (US) | 2025-07-23 | — | — | EP | claimed |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | claimed |
| EP-4419100-A1 | ADJUVANT COMPOSITION COMPRISING STING AGONISTS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-08-28 | — | — | EP | claimed |
| US-20240254208-A2 | COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| CN-116027033-B | Method for detecting bacterial and viral antigens and antibodies based on bacterial sample particles | 吉林大学 | 2024-05-24 | — | — | CN | claimed |
| CN-117815381-A | Carbohydrate modified particles and particle formulations for modulating immune responses | 西北大学 | 2024-04-05 | — | — | CN | claimed |
| EP-4341699-A1 | METHODS OF EVALUATING BRAIN INJURY IN A PEDIATRIC SUBJECT | Abbott Laboratories (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2024059708-A1 | BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND SUPERMILD TRAUMATIC BRAIN INJURY | ABBOTT LABORATORIES (US) | 2024-03-21 | — | — | WO | claimed |
| EP-4308243-A1 | METHODS FOR TREATING CANCER WITH ANTI-ILT3 ANTIBODIES | Merck Sharp & Dohme LLC (US) | 2024-01-24 | — | — | EP | claimed |
| EP-4274614-A1 | ANTI-PD-L1 ANTIBODIES AND FUSION PROTEINS THEREOF | Palleon Pharmaceuticals Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| WO-2022266075-A1 | METHODS AND MATERIALS FOR TREATING CANCER USING CAR CONSTRUCTS WITH AN INTRACELLULAR DOMAIN COMPRISING A STAP DOMAIN AND A KINASE DOMAIN OR A STAP DOMAIN AND A PHOSPHATASE DOMAIN | CARIBOU BIOSCIENCES, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2022245920-A1 | METHODS OF EVALUATING BRAIN INJURY IN A PEDIATRIC SUBJECT | ABBOTT LABORATORIES (US) | 2022-11-24 | — | — | WO | claimed |
| CN-115144581-A | Gel suspension buffer solution, gel solution, detection card and application of gel suspension buffer solution, gel solution and detection card | 北京乐普诊断科技股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| WO-2022197900-A1 | METHODS FOR TREATING CANCER WITH ANTI-ILT3 ANTIBODIES | MERCK SHARP & DOHME LLC (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022150521-A1 | ANTI-PD-L1 ANTIBODIES AND FUSION PROTEINS THEREOF | Palleon Pharmaceuticals Inc. (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022133230-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2022-06-23 | — | — | WO | claimed |
| EP-3999113-A1 | ANTI-PD-L1 ANTIBODIES | Capella Bioscience Ltd (GB) | 2022-05-25 | — | — | EP | claimed |
| EP-3999549-A1 | SIALIDASE-PD-L1-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF | Palleon Pharmaceuticals Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| US-20220153819-A1 | COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN | REGENERON PHARMA (US) | 2022-05-19 | — | — | US | claimed |
| WO-2022081886-A1 | BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28 | XENCOR, INC. (US) | 2022-04-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | SGMS1, UGCG, SGMS2 | LGALS3 391/4885LGALS8 634/4885LGALS4 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.